Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | PTGES | O14684 | 4/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060174 | 0.91 | ROCK2 (0.36) | HRH4HRH3 | |
| SCHEMBL10067408 | 0.88 | BCL6 (0.34) | CDK2 | |
| SCHEMBL13060096 | 0.86 | KLKB1 (0.30) | — | |
| SCHEMBL10067701 | 0.84 | HTRA1 (0.33) | MAPK1 | |
| SCHEMBL2633577 | 0.82 | ROCK2 (0.47) | — | |
| SCHEMBL13060111 | 0.81 | SSTR4 (0.33) | MAPK1HRH4HRH3 | |
| SCHEMBL13060173 | 0.80 | JAK2 (0.31) | — | |
| SCHEMBL13059246 | 0.80 | LRRK2 (0.30) | — | |
| SCHEMBL13059352 | 0.79 | STK17B (0.30) | — | |
| SCHEMBL10067203 | 0.79 | FGFR3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | JAK3, JAK1, JAK2 | MAPK1 416/4885HRH4 2015/4885HRH3 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.